(VIANEWS) – Shares of MDXHEALTH (BEL 20: MDXH.BR) slid by a staggering 24.93% in 10 sessions from €0.37 to €0.28 at 13:24 EST on Tuesday, after two successive sessions in a row of losses. BEL 20 is rising 0.9% to €3,692.88, after five consecutive sessions in a row of losses.
MDXHEALTH’s last close was €0.30, 68.97% under its 52-week high of €0.97.
About MDXHEALTH
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Earnings Per Share
As for profitability, MDXHEALTH has a trailing twelve months EPS of €-0.282.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -156.7%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 114.4%, now sitting on 37.05M for the twelve trailing months.
Moving Average
MDXHEALTH’s worth is way below its 50-day moving average of €0.50 and way below its 200-day moving average of €0.66.
Volume
Today’s last reported volume for MDXHEALTH is 169936 which is 84.17% below its average volume of 374685.
Volatility
MDXHEALTH’s last week, last month’s, and last quarter’s current intraday variation average was a negative 6.24%, a negative 1.09%, and a positive 3.47%.
MDXHEALTH’s highest amplitude of average volatility was 8.46% (last week), 2.95% (last month), and 3.47% (last quarter).
More news about MDXHEALTH (MDXH.BR).
